Tadekinig

Tadekinig is a recombinant human interleukin-18 binding protein (rhIL-18BP) used in the treatment of certain inflammatory conditions. It acts by neutralizing the activity of interleukin-18 (IL-18), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory diseases.

Mechanism of Action

Tadekinig works by binding to IL-18, preventing it from interacting with its receptor on the surface of immune cells. This inhibition reduces the production of interferon-gamma (IFN-γ) and other inflammatory mediators, thereby decreasing inflammation and tissue damage.

Clinical Uses

Tadekinig is primarily used in the treatment of:

• Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD).
• Macrophage activation syndrome (MAS), a severe complication of rheumatic diseases.

Pharmacokinetics

Tadekinig is administered via subcutaneous injection. It has a high affinity for IL-18, and its half-life allows for dosing at regular intervals. The drug is metabolized and excreted primarily through the kidneys.

Adverse Effects

Common side effects of Tadekinig include:

• Injection site reactions
• Headache
• Fatigue
• Upper respiratory tract infections

Serious adverse effects are rare but may include:

• Increased risk of infections due to immunosuppression
• Hypersensitivity reactions

Research and Development

Tadekinig is currently under investigation for its potential use in other inflammatory and autoimmune conditions, such as Crohn's disease and rheumatoid arthritis. Ongoing clinical trials are assessing its efficacy and safety in these and other indications.

Also see

• Interleukin-18
• Cytokine
• Autoimmune disease
• Biologic therapy